|
|
 |
|
Viewing report
|
|
|
|
Reimbursement in the Asthma market -how important is it as a determinant of success?
Datamonitor, Sep 2001
This brief provides an overview of the reimbursement and pricing regulations, of the five major European markets, Japan and the US. The reimbursement of asthma products within each of these markets is discussed, and an analysis of the impact of future changes in regulatory practices is provided. Whilst many aspects of reimbursement are applicable to all diseases, asthma stands out as an area of particular interest. As a chronic, long-term disease asthma places a heavy burden on a country’s healthcare expenditure. In the US, for example, direct health care costs for asthma, such as prescription medications and hospital services, account for more than $9.8 billion annually and indirect costs, such as lost productivity, account for $2.8 billion (American Lung Association). It is this economic burden that is driving governments to examine more effective means to not only reduce costs in this disease area but also to transfer a proportion of the costs to the asthma patient.
Customers who bought this item also bought
The 2003 Casino and Gaming Market Research Handbook
HIV in South Africa
Stakeholder Insight: Asthma - Combination Therapy Appropriate for Everyone?
Market Dynamics 2001: Hormonals
Market Dynamics: Anti-asthmatics - Preparing for Slow Market Growth
Stakeholder Perspectives: Asthma - Improvements to Combination Inhalers Will Satisfy a Growing Patient Base
Strategic Perspectives 2001: Vaccines
Strategic Perspectives 2002: Colorectal Cancer Cost Analysis
Strategic Perspectives 2001: Breast Cancer Cost Analysis
Commercial Insight: Asthma and Copd - Combinations breathe life into the asthma and Copd markets
Reimbursement in Europe, Japan and the US: The Impact of Cost Shifting on Pharmaceutical Strategies
Market Dynamics 2000: Allergic Rhinitis: Effects of Major Patent Expiries On An Expanding Market
|
|
|
|
